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Abstract
Background: Recent reports indicate that a subgroup of tumor cells named cancer stem cells (CSCs) or tumor initiating
cells (TICs) are responsible for tumor initiation, growth and drug resistance. This subgroup of tumor cells has self-renewal
capacity and could differentiate into heterogeneous tumor cell populations through asymmetric proliferation. The idea of
CSC provides informative insights into tumor initiation, metastasis and treatment. However, the underlying mechanisms
of CSCs regulating tumor behaviors are unclear due to the complex cancer system. To study the functions of CSCs in the
complex tumor system, a few mathematical modeling studies have been proposed. Whereas, the effect of
microenvironment (mE) factors, the behaviors of CSCs, progenitor tumor cells (PCs) and differentiated tumor cells (TCs),
and the impact of CSC fraction and signaling heterogeneity, are not adequately explored yet.
Methods: In this study, a novel 3D multi-scale mathematical modeling is proposed to investigate the behaviors of
CSCsin tumor progressions. The model integrates CSCs, PCs, and TCs together with a few essential mE factors. With
this model, we simulated and investigated the tumor development and drug response under different CSC
content and heterogeneity.
Results: The simulation results shown that the fraction of CSCs plays a critical role in driving the tumor
progression and drug resistance. It is also showed that the pure chemo-drug treatment was not a successful
treatment, as it resulted in a significant increase of the CSC fraction. It further shown that the self-renew
heterogeneity of the initial CSC population is a cause of the heterogeneity of the derived tumors in terms of the
CSC fraction and response to drug treatments.
Conclusions: The proposed 3D multi-scale model provides a new tool for investigating the behaviors of CSC in
CSC-initiated tumors, which enables scientists to investigate and generate testable hypotheses about CSCs in
tumor development and drug response under different microenvironments and drug perturbations.
Background
The mechanisms of tumor initiation, progression, metasta-
sis and drug resistance remain elusive due to the complex
system of tumors. Recent studies have shown that a sub-
population of tumor cells, named cancer stem cells (CSCs)
or tumor initiating cells (TICs) tumor are responsible for
tumor development and drug resistance [1-3]. The CSC
concept is still controversial, as it is difficult to discover
and validate cancer stem cells, particularly their unlimited
self-renewal and differentiation capabilities [1]. However,
CSCs have been being isolated from more and more
cancers [2], since first discovered in the acute myeloid
leukemia (AML) by using CD34++/CD38- biomarkers [3].
Recently, the breast CSCS were identified by using CD44+
CD24-/low biomarkers in [4], and the colon CSCS were
also reported [5]. CSCs are believed to have strong self-
renewal capacity, could differentiate into heterogeneous
tumor populations through asymmetric division [6,7], and
are responsible for drug resistance and metastasis [8,9].
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Reportedly, CSCs are heterogeneous with different self-
renewal and tumor formation abilities, which might be
caused by varying activation intracellular signaling (e.g.,
Wnt, Shh and Stat3) due to the diverse concentrations of
external mE factors [10,11].
However the roles of CSCs in tumor development
remain unknown because of tumor complexity in multiple
levels, including signaling transduction, cell-cell communi-
cation, and cell-microenvironment interactions. The math-
ematical simulation models have been powerful tools for
understanding the tumor systems [12]. In general, the
existing mathematical models of the tumor development
can be grouped into three major categories: discrete, con-
tinuous and hybrid. The discrete models, e.g., cellular
automata [13] and Glazier and Graner model [14], simu-
late cell behaviors individually with a group of rules. The
continuous models employ ordinary or partial differential
equations to simulate the behaviors of tumor cell popula-
tions and dynamics of mE factors [15,16]. The hybrid
models are the combination of the discrete (for modeling
cells) and continuous (for modeling mE factors) models
[12]. A few mathematical simulation studies have been
developed to study CSCs functions in tumor development
[17-20]. Whereas, the interactions between mE factors and
CSCs, PCs and TCs, the impact of the heterogeneity and
fraction of CSCs, have not been adequately considered in
the mathematical modeling.
Herein, a 3D multi-scale mathematical modeling is pro-
posed to study the functions of CSCs in tumor develop-
ment. The model, extended our previous concept [21],
enables us to study the roles of CSCs in tumor progression
and chemo-drug resistance by simulating the tumor
growth initiated by a set of heterogeneous CSC popula-
tions. The overview of the proposed multi-scale model is
shown in Figure 1. In brief, mE factors are considered,
including nutrients (e.g., oxygen and glucose), tumor
angiogenesis factors (TAF), matrix degrading proteolytic
enzyme (MDE), extracellular matrix (ECM), tissue pres-
sure [22], and motility of cells are described in the molecu-
lar scale. The interactions between mE factors and cancer
cells are shown in Figure 2. The behaviors of endothelial
and cancer cells are described by the cellular automata in
the cellular scale. The cancer cells are represented by a
hierarchical organization of cellular subtypes [23,24],
including CSC, a series of intermediate PCs and TCs, each
endowed with different biological traits. At the tissue level,
the tumor volume, shape and spatial distributions of
tumor cells are investigated.
Figure 1 The schematic of the 3D multiscale model and the implementation. The molecular scale describing the diffusion and reaction
processes of mE factors with PDEs. The cellular level models the behaviours of cells with a 3D cellular automata. The tissue level visualizes the
whole tumor morphology.
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Methods
The PDE system characterizing reaction-diffusion process
of mE factors
Five mE factors are considered in this model, including
nutrients (n), tumor angiogenic factor (TAF) (c), matrix
degrading proteolytic enzyme (MDE) (m), extracellular
matrix (ECM) ( f ), and tissue pressure (p). A system of
PDEs is used to delineate the diffusion and reactions
mE factors. The cΩ is defined as follows.
χ(x) =
{
1 , x ∈ 
0 , x /∈ 
The diffusion and reaction of nutrients are modeled
by the quasi-steady equation with non-zero Dirichlet
boundary conditions [25,26]. Since they are much smal-
ler comparing to cells, nutrient molecules diffuse quickly











where Dn is the diffusion rate of nutrient molecules,
and λnpp, λ
n
pa denote the nutrient molecules transferring
rates from pre-existing and neo-vasculature vessels. The
λnb is the nutrient molecule binding rate to fibronectin; λ
n
u
is the uptake rate by cells, and it is different for specific
types of cells. The cΣc is an indicator function that equals
to 1 at the new generated vessels. The term (1-p) is used
to indicate the difference of nutrient molecule transfer
with different pressure, and (1-n) is to reflect nutrient
molecules’ saturation effect.
The TAF is selected by tumor cells, and during its dif-
fusion, TAF will be either degrade naturally or captured
















−→n |∂ = 0
(2)
where Dc is the diffusion rate of TAF, ∂N is the
boundary of necrotic and viable regions, the n is the
unit outer normal direction, λcpN, λ
c
pV are the TAF secre-
tion rates by dying and viable tumor cells, respectively;
λcu is the uptake rate by endothelial cells, and λ
c
d is the
rate of natural degradation.
The ECM, such as fibronectin, represents a set of
binding molecules that do not diffuse but increase the
tumor cell adhesion. The concentration of ECM mole-













f |t=0 = 1
(3)
Where the λfp, λ
f
sp denote fibronectin production rates
by tumor and endothelial cells, respectively, and λfd is
the ECM degradation rate by MDE.
MDE is secreted by endothelial cells and viable tumor
cells to degrade ECM. The MDE diffusion and reaction











−→n |∂ = 0
(4)
In this equation, Dm is the diffusion coefficient, λ
m
p
and λmsp denote MDE secretion rates by the endothelial
cells and viable tumor cells, and λmd is the MDE decay
rate.
The cell velocity is resulted from the different cell
proliferation at different regions, and is described by
using the following Darcy-Stokes law [27].
−→u = −∇p , p|∂ = 0 (5)
And the velocity field follows the divergence equation:
∇ · −→u = χV (n − λa) − χNλN (6)
where, la and lN are the volume loss rates caused by
cellular apoptosis. The first term on the right of equa-
tion (6) is the source effect, while the second term can
Figure 2 The interactions between micro-environmental (mE)
factors and tumor cells. The outer circle stands for mE factors
being considered at the molecular level, the inner circle
corresponds to the processes investigated at the cellular level. The
interrelations are denoted by the solid arrows.
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be considered as the sink effect. The diffusion of pressure
is obtained by taking the divergence operation on both
sides of equation (5), and combined with equation (6):{
0 = ∇2p + (n − λa)χV − λNχN
p|∂ = 0
(7)
In the implementation, the finite element method is
used to solve PDEs with diffusion item ∇2 [28]. The ECM
equation is solved by the 2nd order total variation Runge-
Kutta method [29]. The time interval, t, is calculated to












where l = 0.1 is the spatial interval, Vi is the function
defined on the TAF, ECM, and cell velocity in [25], and
−→ui is the cell velocity at i-th spatial point [25].
3D Cellular Automata
For simplicity, cells are limited to interact with its six
immediate orthogonal neighbor grids such that the cell
can move or proliferate, based on probabilities calcu-
lated from the distribution of surrounding mE factors.
Figure 3 shows a flowchart of cell behavior under inter-
actions with mE factors and cell lineage in proliferation.
Specifically, for a cell being at location k:
1) Check available (empty) neighbor locations.
2) If there is no available neighbor location, go to step 8).
3) Calculate the motion probabilities to the m (m <= 6)
available neighbor locations as: qi = ni/fi, i = 0, 1, ..., m,
where q0 means the probability of staying at the same
location.
4) Denote q′k =
∑k
i=1










i ], i = 1, 2, ..., m.
7) Pick up a number r randomly from [0, 1], then
move the cell to the i-the neighbor location where r
belongs to.
8) Update the cell age, and then check if the cell is
mature to divide. If yes, add one new cell with right cell
type to a neighbor location with the above rules. Check
the mE conditions to determine if the cell should enter
the quiescent or death status.
Simulation of chemotherapy
In simulation of chemotherapy, all cancer cells (CSCs,
PCs, TCs) can be killed by chemo drugs with different
doses. Since the diffusion and reaction processes of the
drug molecules resemble that of nutrients, we use the
same diffusion-reaction equation for drugs. We assume
that TCs proliferation is reduced due to the effects of
drugs, while CSC proliferation is accelerated as activated
by the volume loss due to the drug effect, which is paral-
lel to the normal stem cell functions [30]. We adjust the
proliferation age of each cell subtype in such a way to sti-
mulate the reaction of tumor cells to chemotherapy.
The Gompertz curve fitting
The tumor growth pattern is fitted by using the Gom-
pertz curve, which shows slow change in the beginning
and the end of tumor growth [31]. Though for tumors
that undergo angiogenesis, a plateau in growth is not
necessarily reached, the Gompertz cure is an appropriate
choice in modeling the initial phase of the tumor
growth with limited access to nutrients. Mathematically
the tumor growth is represented as:
yˆ(t) = y0ek(1−e
−b(t−t0)) (9)
where y0 is the volume of tumor at time t0, while posi-
tive constants k, b denote the axis displacement and
growth speed. The least square is used to determine the
optimal parameters as follows:




(yˆ(ti) − yi)2 (10)
Here, yˆ(t) is the tumor volume growth function
defined in equation (9), yi is the measured volume of
tumor at time point i, obtained either from biological
experiments or by computer simulation, and N is the
number of available measurements.
Measurements of tumor development
The tumor properties are evaluated by following mea-
surements: proliferation potential (PP), time to reach
potential (TtP), average aggressive index (AAI), and
average fitting error (AFE). PP is defined as (9):
PP = lim
t→+∞ yˆ(t) = y0e
k (11)
The PP value could not predict the final volume of a
tumor because of many unforeseen contributing factors
when tumors grow large. However, it can be used to
compare the potential volume of tumors in a relative
sense. TtP is estimated by solving an inverse problem of
(9), that is, by searching the time when yˆ(t) reaches PP
for the first time:
TtP = inf
{
t > 0 : yˆ(t) ≥ PP} (12)
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Figure 3 The flowchart of control in the multiscale model of CSC-initiated tumor development. (A) Each cell evolves according to their
life cycle under the conditions confined by the PDE system. Necrosis occurs when cell death is induced by hypoxia. (B) Hierarchical organization
of different cell subtypes and their proliferative kinetics. Cancer stem cells (CSC) expand their own population by symmetric proliferation to two
identical daughter cells still with CSC-like traits and expand the whole tumor through asymmetric differentiation to progenitor cells (PC) and
terminally differentiated cells (TC) in this model. Similarly, PCs contribute to the constitution of the tumor in a similar way, but do not reversibly
produce CSCs according to the hierarchical organization hypothesis. The TCs are assumed to either proliferate or be apoptotic at each time
point without ability to divide into any other subtypes. The parameters above the arrows indicate the occurrence probability of the referred
event at each time point.
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Here, Sisurface and V
i
tumor stand for the surface area and
volume of the tumor at time point i, which are repre-
sented by the number of cells on the surface and the
total number of cells composing the tumor respectively.
The performance of the curve fitting is assessed by AFE,









Simulation of tumor development under different CSCs
contents
To investigate tumor development initiated from a set of
tumor cells with different CSC contents (or fractions),
herein, we simulated tumor growth with pure CSCs (CSCs
only, initiated from ~20 CSCs) and unsorted (mixtures of
CSCs and non-CSCs) tumor cells (200 tumor cells in
which 4% are CSCs), respectively. Figure 4 shows the
dynamics of tumor growth and concentration profiles of
mE factors over the time under different CSC contents. As
shown, the tumor initiated from the mixed tumor cells
grows faster than that tumors initiated from pure CSCs.
Whereas the tumors initiated from pure CSCs have more
spiky morphology. This might be caused by biased migra-
tion of CSCs toward locations (without the limitation of
other tumor cells) with a higher nutrient concentration
and lower ECM concentration, which affect the tumor
geometric morphology. We conducted growth curve fit-
ting of the simulation results and found that the tumor
initiated from pure CSCs has an elevated proliferation
potential, though it takes a longer time to grow to its limit
size (Figure 5). Tumors also exhibits a stronger
Figure 4 Simulation of tumor development under different CSC contents. (A) Time evolution of tumors initiated by pure CSCs and
unsorted tumor cells. (B) The corresponding concentration profiles of micro-environmental (mE) factors.
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aggressiveness compared to tumors initiated from the
mixed tumor cells (Figure 5).
Important parameters to tumor growth
In Table 1, all parameters of the proposed multi-scale
model of tumor growth are listed. These parameters are
determined mostly from either literature or experimental
data. We performed sensitivity analysis to discover impor-
tant parameters to tumor growth initiated from pure
CSCs. The parameter values were perturbed in a range of
10%. Figure 6 shows the effects of parameters on the





p , and Dc are sensitive to the tumor growth,
and some parameters proliferation abilities parameters,
i.e., KCCP and KPP are also sensitive to tumor growth.
Tumor response to drug treatment
The effect of chemo-drug treatment on tumor develop-
ment and CSC fraction is also investigated. Figure 7 shows
the dynamics of tumor development under chemo-drug
treatment. As can be seen, the solid tumor shrinks during
the drug treatment, whereas the CSC fraction increases.
The simulation results also reveal that tumors will grow
fast to half of its original volume after stop the drug treat-
ment. This fast relapse may be because some CSCs reside
in the interior of a tumor where drug molecules are not
accessible. It might be due to that the fast proliferating
non-CSCs dominate the outer rim of a tumor, and drug
molecules will first kill the non-CSCs in order to reach the
area where CSCs tend to gather. The quick relapse of
tumor, once the treatment stops, as observed in our simu-
lations, can be explained by the escape of CSCs from ther-
apeutic interventions. The decreased percentage and lower
proliferation rate of CSCs may be because these interior
CSCs reside in a region where the access to nutrients is
limited.
Simulation of CSC self-renewal heterogeneity in tumor
development
To investigate the heterogeneity of CSC self-renewal
ability, we further extend our model as follows: 1) a
tumor is initiated from a single CSC; 2) the initiating
CSCs have different self-renewal abilities that are pro-
portional to the Gaussian distribution with different
means: p ∝ G(μ, σ ), where G(μ, σ ) is a Gaussian with
mean μ and variance σ 2; and 3) the newly formed CSCs
during tumor development will obtain a mean value
randomly sampled from the G(μp, σ ), where μp is the
mean of its parent CSC. In our simulation, we set
μ = 0.25, 0.5, and 0.75, respectively, to indicate the rela-
tive low, medium, and high self-renewal ability of initiat-
ing CSCs (with fixed σ = 0.1). The simulation starts
from a single CSC to 30 days, then the same chemo-
drug treatment is applied. The virtual chemo-drug
Figure 5 Quantitative comparison between tumor development initiated from pure CSCs and unsorted tumor cells. The proliferation
potential, time needed to reach potential, average aggressive index, and average fitting error of tumors are compared between two kinds of
tumors in five simulations.
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treatment will be stopped when 85% of tumor cells are
killed. Figure 8 shows the simulation results for the size
and fraction of CSCs of tumors initiated from CSCs
with different self-renewal abilities. As shown, before
chemo-drug treatment, the tumor initiated from CSCs
with high self-renewal ability has an average bigger
tumor volume (about 1.5 fold), whereas the difference of
the CSC fraction is about 2 fold. After chemo-drug
treatment, the difference in the CSC fraction is signifi-
cantly increased to about 3 fold, though the CSC frac-
tions of all tumors are increased significantly comparing
to those before chemo-drug treatment. The results indi-
cated that though the pure chemo-drug treatment could
reduce the size of tumor, it might also increase the
aggressiveness of tumor due to the increased fraction of
CSCs, especially for the tumor with the CSCs that have
high self-renewal ability. Therefore, the combinations of
chemo-drugs and anti-CSCs drugs are needed to achieve
better treatment outcomes.
Discussion & conclusions
Here, a multi-scale and multi-factorial computational
model is established in 3D space to study the behaviors
and roles of CSCs in leading tumor development. The
model is implemented at three hierarchical scales (mole-
cular, cellular, tissue scales). The molecular subsystem
characterizes the diffusion and reaction processes of mE
factors by using PDEs. The cellular level subsystem
simulates the proliferation and migration of all cancer
cells and endothelial cells, considering the availability of
mE factors, with a 3D cellular automaton. The tissue
level subsystem evaluates the temporal and spatial
Table 1 Model parameters.
Parameter Symbol Parameter Annotation Parameter Value Reference
Dn Diffusion rate of Nutrient 1.0 P. Macklin et al. (2009)
Dc Diffusion rate of TAF 100 Estimated
Dm Diffusion rate of MDE 1.0 P. Macklin et al. (2009)
λnu Uptake rate of Nutrient [0.2, 0.5, 0.33, 0.67, 1, 1] X. Zheng et al. (2005); Estimated
λnb Binding rate of nutrient 2.5·e-3 Estimated
λnpa Nutrient transfer rate from neo-vasculature 0.05 X. Zheng et al. (2005); Estimated
λnpp Nutrient transfer rate from existing vessel 0.01 Estimated
λcpN TAF secretion rate by dying cells 0.05 Estimated
λcpV TAF secretion rate by viable cells 0.004 Estimated
λcd TAF degradation rate 0.01 P. Macklin et al. (2009)
λcu TAF uptake rate by endothelial cells 0.025 P. Macklin et al. (2009)
λmp MDE secretion rate by viable cells {50, 100, 150} P. Macklin et al. (2009); Estimated
λmsp MDE secretion rate by endothelial cells 1.0 P. Macklin et al. (2009)
λmd MDE degradation rate 10 P. Macklin et al. (2009)
λ
f
p ECM secretion rate by viable cells 0.1 P. Macklin et al. (2009)
λ
f




ECM degradation rate 0.01 P. Macklin et al. (2009)
la Volume loss rate due to apoptosis 0~0.00013 Estimated
lN Volume loss rate due to necrosis 0.25 X. Zheng et al. (2005)
θa Nutrient dose for cell survival {0.1, 0.17, 0.25} X. Zheng et al. (2005); Estimated
θd Maximum drug concentration for cell survival {0.25, 0.27, 0.375} Estimated
[KCC, KCCP, KCP, KCT] CSC proliferation probabilities {0.6, 0.25, 0.1, 0.05} Estimated
[KPP, KPT] PC proliferation probabilities {0.25, 0.75} Estimated
[KTT, dT] TC proliferation probability [1- la, la] Estimated
Ap Relative proliferation ages [1, 0.4, 1, 0.2] Estimated
Gm Maximum generations a cell can divide [250, 50, 25] Estimated
Cs Constant for cell size scaling 10·e-5 Estimated
NOTE:
P. Macklin et al. (2009): Macklin, P., et al., Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math Biol, 2009. 58(4-5): p. 765-98.
X. Zheng et al. (2005): Zheng, X., S.M. Wise, and V. Cristini, Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-
element/level-set method. Bull Math Biol, 2005. 67(2): p. 211-59.
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variations of tumor morphology by, four indices. The
model can be conveniently expanded to a particular
application to generate testable hypotheses.
The simulation studies based on the multi-scale
model could provide important insights into tumor
development and treatment. For example, the simula-
tion indicated that tumors in mice model initiated by
the sorted CSC population had stronger aggressiveness
and proliferation potential comparing to tumors from
unsorted cancer cells. Also the simulation demon-
strated that the neo-vasculature could grow into the
interior of a tumor, suggesting a possibility of deliver-
ing drugs via neo-vasculature to target the CSCs in the
interior of tumors, besides the anti-angiogenic therapy
that elicits increased local invasion and distant metas-
tasis of tumors [32,33]. In addition, the simulation
indicated that pure chemo-drug treatment may
increase the fraction of CSCs significantly, especially
for the tumor with CSCs of high self-renewal ability,
and consequently, the tumor residual will be more
chemo-resistant and aggressive. Thus, a combination
of chemo-drugs with CSC inhibition drugs would be
more effective in cancer treatment without increasing
tumor drug-resistance and aggressiveness.
Many parameters in our model were defined based on
general understanding of tumor development through
literature mining in this study, as in many other model-
ing studies. Despite limited experimental data used in
defining the parameters, the model we proposed is still
valid. It enables us to identify important CSCs behavior
and interactions with interested mE factors, and to vir-
tually test hypotheses that cannot be done in an animal
model. The simulation studies based on the model can
lead to new insight of CSCs in tumor development and
Figure 6 Sensitivity analysis (A) The sensitivity analysis of the continuous parameters. (B) The sensitivity analysis of the proliferation
related parameters.
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shed light on the treatment. As more experimental data
become available through our studies, the parameters
can be better defined and calibrated, and the resulting
model will be better predictable.
Several improvements of the proposed 3D tumor
growth model will be conducted in the future work. Can-
cer is a complex and heterogeneous disease. CSCs from
different types of cancer might have different functions
Figure 7 Simulation of chemo-drug therapy response. (A) A 9-week treatment to a tumor initiated from pure CSCs. The tumor volume first
reduces fast, then remains stable during drug treatment; whereas it grows back quickly after the treatment stops. (B) The evolution of the CSC
fraction in the process. (C) The 3D morphology of the tumor at different stages of the treatment.
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and regulatory signaling pathways. With more data of
cancer-specific signaling pathways, cell differentiation
lineages, stromal cells, and detailed cell-cell interactions
becoming available, the proposed model could be
extended to study the CSCs in specific cancer types. Also
the cell shape could be taken into account as it plays an
Figure 8 Comparison of tumor development initiated from single CSCs with heterogeneous self-renewal ability. (A) Average size of
tumors and (B) average CSC fractions of tumors initiated from a single CSC with relative low (0.25), medium (0.5) and high (0.75)self-renewal
ability. (C) Average CSC fractions of tumors before and after chemo-drug treatment.
Li et al. BMC Systems Biology 2013, 7(Suppl 2):S12
http://www.biomedcentral.com/1752-0509/7/S2/S12
Page 11 of 12
important role in interactions between cells and mE fac-
tors, particularly when the cell density is high and causes
shape deformation and cell-cell interaction through cell
surface markers. On the other hand, relevant regulatory
or signaling pathways could be integrated to refine the
modeling. In addition, specific drug effects on different
cell cycles and cell types could be considered.
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